Interim report Q3/2022: A broader role for ColdZyme adds potential for the future
Significant events during the quarter
Significant events after the quarter
| || |
Other events during the quarter
| || |
”The study that has been published in Respiratory Research shows ColdZyme has the potential to move from a cold remedy product to a complement to vaccines in the protection against Covid-19. After a couple of very hard years, many signs now indicate that Enzymatica has passed the austerity caused by the pandemic. We see good possibilities of expanding in new and existing markets, we have a good organization in place, and strong business partners. I am convinced that there are a number of exciting and successful years ahead of us”, said Claus Egstrand, CEO of Enzymatica.
The full year-end report is available on: www.enzymatica.com/investors/financial-reports
This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET
on 2 November 2022.
For more information, please contact:
Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: email@example.com
Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email: firstname.lastname@example.org
Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica’s Certified Adviser is Erik Penser Bank. Tel: +46 8 463 83 00 Email: email@example.com